{"id":7530,"date":"2025-04-10T09:06:07","date_gmt":"2025-04-10T09:06:07","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7530"},"modified":"2025-04-10T09:06:07","modified_gmt":"2025-04-10T09:06:07","slug":"pilar-eroles-asensio","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/pilar-eroles-asensio\/","title":{"rendered":"Pilar Eroles Asensio"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container fusion-parallax-none nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ededed;background-image: url(&quot;https:\/\/www.incliva.es\/wp-content\/uploads\/2021\/01\/fondo.jpg&quot;);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><h3>Dr. Pilar Eroles Asensio<\/h3>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:3px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-2\" style=\"transform:translate3d(0,0,0);\"><h5><span style=\"color: #3D44AC;\">Principal Investigator<br \/>\nResearch Group on Breast Cancer Biology<br \/>\n<\/span><\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-3\" style=\"transform:translate3d(0,0,0);\"><h4 style=\"text-align: justify;\">Presentation<\/h4>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:75% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 2.56%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 2.56%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:75% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;border-width: 0 0 0 2px;border-color:#9da0d2;border-style:solid;padding: 4% 4% 4% 4%;\">\n<div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border-radius:5px;\"><img src=\"\/wp-content\/uploads\/2024\/01\/Pilar-Eroles-Asensio_FIH12_COIP.jpg\" class=\"img-responsive\"\/><\/span><\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;\"><\/div>\n<div class=\"fusion-text fusion-text-4\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">Principal<br \/>\nInvestigator<\/h5>\n<div style=\"text-align: center;\">Dr. Pilar Eroles Asensio<\/div>\n<p style=\"text-align: center;\"><a href=\"mailto:pilar.eroles@uv.es\">pilar.eroles@uv.es<\/a><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 4% !important;padding-right : 4% !important;margin-right : 7.68%;padding-bottom : 4% !important;padding-left : 4% !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-1{width:25% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-fullwidth.fusion-builder-row-1 { overflow:visible; }.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-5\" style=\"transform:translate3d(0,0,0);\"><h5>Publications<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-1 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-1 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-1 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav,.fusion-tabs.fusion-tabs-1 .nav-tabs,.fusion-tabs.fusion-tabs-1 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-aaed6aa0bcbb8358683\" aria-selected=\"true\" id=\"fusion-tab-2023\" href=\"#tab-aaed6aa0bcbb8358683\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-7f7a198d6635ee55aa4\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2022\" href=\"#tab-7f7a198d6635ee55aa4\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-1bf76dad2d959807eac\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2021\" href=\"#tab-1bf76dad2d959807eac\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-aaed6aa0bcbb8358683\" aria-selected=\"true\" id=\"mobile-fusion-tab-2023\" href=\"#tab-aaed6aa0bcbb8358683\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2023\" id=\"tab-aaed6aa0bcbb8358683\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nClinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical Anti-HER therapies. Tapia M, Hernando C, Mart\u00ednez M, Burgu\u00e9s O, Tebar-S\u00e1nchez C, Lameirinhas A, Agreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Cancers. 2023 Sep 12;15(18):4522. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15184522' target='_blank'>10.3390\/cancers15184522<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37760491' target='_blank'>37760491<\/a><\/p>\n<p>Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials &#038; Interfaces. 2023 Aug 16;15(32):38323-38334. doi: <a href='https:\/\/doi.org\/10.1021\/acsami.3c07541' target='_blank'>10.1021\/acsami.3c07541<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37549382' target='_blank'>37549382<\/a><\/p>\n<p>Generation and characterization of trastuzumab\/pertuzumab-resistant HER2-Positive breast cancer cell lines. Sanz-Alvarez M, Luque M, Morales-Gallego M, Crist\u00f3bal I, Ram\u00edrez-Merino N, Rangel Y, Izarzugaza Y, Eroles P, Albanell J, Madoz-G\u00farpide J, Rojo F. International Journal of Molecular Sciences. 2023 Dec 22;25(1):207. doi: <a href='https:\/\/doi.org\/10.3390\/ijms25010207' target='_blank'>10.3390\/ijms25010207<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38203378' target='_blank'>38203378<\/a><\/p>\n<p>High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: <a href='https:\/\/doi.org\/10.3390\/ijms24043601' target='_blank'>10.3390\/ijms24043601<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36835014' target='_blank'>36835014<\/a><\/p>\n<p>miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15072138' target='_blank'>10.3390\/cancers15072138<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37046799' target='_blank'>37046799<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7530-1 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7530-1 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7530-1.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7530-1 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7530-1 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7530-1 .panel-title a:hover, #accordion-7530-1 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7530-1 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7530-1 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7530-1\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"6a83cc2a72d62e106\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7530-1\" data-target=\"#6a83cc2a72d62e106\" href=\"#6a83cc2a72d62e106\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2023<\/span><\/a><\/h4><\/div><div id=\"6a83cc2a72d62e106\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nSynthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer. Garc\u00eda A, Torres-Ruiz S, Vila L, Villarroel-Vicente C, Bernabeu A, Eroles P, Cabedo N, Cortes D. RSC Medicinal Chemistry. 2023 Oct 4;14(11):2327-2341. doi: <a href='https:\/\/doi.org\/10.1039\/d3md00385j' target='_blank'>10.1039\/d3md00385j<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38020071' target='_blank'>38020071<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-7f7a198d6635ee55aa4\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2022\" href=\"#tab-7f7a198d6635ee55aa4\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2022\" id=\"tab-7f7a198d6635ee55aa4\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nAntagonists of the Mu-opioid receptor in the cancer patient: fact or fiction?. Belltall A, Mazzinari G, Diaz-Cambronero O, Eroles P, Navarro M. Current Oncology Reports. 2022 Oct;24(10):1337-1349. doi: <a href='https:\/\/doi.org\/10.1007\/s11912-022-01295-z' target='_blank'>10.1007\/s11912-022-01295-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35648340' target='_blank'>35648340<\/a><\/p>\n<p>CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Garcia-Foncillas J, Rojo F. Journal of Clinical Medicine. 2022 Mar 14;11(6):1610. doi: <a href='https:\/\/doi.org\/10.3390\/jcm11061610' target='_blank'>10.3390\/jcm11061610<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35329936' target='_blank'>35329936<\/a><\/p>\n<p>MicroRNAs as a clue to overcome breast cancer treatment resistance. Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Cancer Metastasis Reviews. 2022 Mar;41(1):77-105. doi: <a href='https:\/\/doi.org\/10.1007\/s10555-021-09992-0' target='_blank'>10.1007\/s10555-021-09992-0<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34524579' target='_blank'>34524579<\/a><\/p>\n<p>miR-99a-5p modulates doxorubicin resistance via the COX-2\/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: <a href='https:\/\/doi.org\/10.1002\/cac2.12352' target='_blank'>10.1002\/cac2.12352<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35997029' target='_blank'>35997029<\/a><\/p>\n<p>mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: <a href='https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0545' target='_blank'>10.1158\/1541-7786.MCR-21-0545<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35348729' target='_blank'>35348729<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7530-2 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7530-2 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7530-2.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7530-2 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7530-2 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7530-2 .panel-title a:hover, #accordion-7530-2 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7530-2 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7530-2 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7530-2\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"2a29055b7f6e5d396\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7530-2\" data-target=\"#2a29055b7f6e5d396\" href=\"#2a29055b7f6e5d396\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2022<\/span><\/a><\/h4><\/div><div id=\"2a29055b7f6e5d396\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nOpioid receptor expression in colorectal cancer: a nested matched case-control study. Belltall A, Mazzinari G, Garrido-Cano I, Giner F, Mari A, Eroles P, Argente-Navarro M, Cata J, Diaz-Cambronero O. Frontiers in Oncology. 2022 Apr 6;12:801714. doi: <a href='https:\/\/doi.org\/10.3389\/fonc.2022.801714' target='_blank'>10.3389\/fonc.2022.801714<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35463331' target='_blank'>35463331<\/a><\/p>\n<p>Role of SALL4 in HER2+breast cancer progression: regulating PI3K\/AKT Pathway. Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. International Journal of Molecular Sciences. 2022 Oct 31;23(21):13292. doi: <a href='https:\/\/doi.org\/10.3390\/ijms232113292' target='_blank'>10.3390\/ijms232113292<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36362083' target='_blank'>36362083<\/a><\/p>\n<p>Solid tumor opioid receptor expression and oncologic outcomes: analysis of the cancer genome atlas and genotype tissue expression Project. Belltall A, Zuniga-Trejos S, Garrido-Cano I, Eroles P, Argente-Navarro M, Buggy D, Diaz-Cambronero O, Mazzinari G. Frontiers in Oncology. 2022 Mar 10;12:801411. doi: <a href='https:\/\/doi.org\/10.3389\/fonc.2022.801411' target='_blank'>10.3389\/fonc.2022.801411<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35359418' target='_blank'>35359418<\/a><\/p>\n<p>Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: <a href='https:\/\/doi.org\/10.1126\/sciadv.abk2746' target='_blank'>10.1126\/sciadv.abk2746<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35594351' target='_blank'>35594351<\/a><\/p>\n<p>Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MA, Cros S, Chirivella I, Domenech M, Figols M, Gonzalez-Billalabeitia E, Jimenez Peralta D, Rodriguez-Carunchio L, Garcia-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Cancers. 2022 Sep 29;14(19):4757. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14194757' target='_blank'>10.3390\/cancers14194757<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36230681' target='_blank'>36230681<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-1bf76dad2d959807eac\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2021\" href=\"#tab-1bf76dad2d959807eac\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2021\" id=\"tab-1bf76dad2d959807eac\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nCircadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falco A, Van&#8217;t Veer LJ, Schmidt M, Quigley DA, Borresen-Dale AL, Kristensen VN, Balmain A, Climent J. NPJ Breast Cancer. 2021 Sep 10;7(1):118. doi: <a href='https:\/\/doi.org\/10.1038\/s41523-021-00329-2' target='_blank'>10.1038\/s41523-021-00329-2<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34508103' target='_blank'>34508103<\/a><\/p>\n<p>Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2020.100039' target='_blank'>10.1016\/j.esmoop.2020.100039<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33477007' target='_blank'>33477007<\/a><\/p>\n<p>Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients. Sanz-Alvarez M, Cristobal I, Luque M, Santos A, Zazo S, Madoz-Gurpide J, Carames C, Chiang C, Garcia-Foncillas J, Eroles P, Albanell J, Rojo F. Cancers. 2021 Mar 12;13(6):1246. doi: <a href='https:\/\/doi.org\/10.3390\/cancers13061246' target='_blank'>10.3390\/cancers13061246<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33809005' target='_blank'>33809005<\/a><\/p>\n<p>Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: <a href='https:\/\/doi.org\/10.1021\/acssensors.0c02222' target='_blank'>10.1021\/acssensors.0c02222<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33599490' target='_blank'>33599490<\/a><\/p>\n<p>Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: <a href='https:\/\/doi.org\/10.3390\/ijms22157812' target='_blank'>10.3390\/ijms22157812<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34360578' target='_blank'>34360578<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7530-3 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7530-3 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7530-3.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7530-3 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7530-3 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7530-3 .panel-title a:hover, #accordion-7530-3 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7530-3 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7530-3 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7530-3\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"518ff8cea25d046e1\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7530-3\" data-target=\"#518ff8cea25d046e1\" href=\"#518ff8cea25d046e1\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2021<\/span><\/a><\/h4><\/div><div id=\"518ff8cea25d046e1\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nPreclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez L, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clinical Cancer Research. 2021 Sep 15;27(18):5096-5108. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2915' target='_blank'>10.1158\/1078-0432.CCR-20-2915<\/a>. PMID:<a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34385295' target='_blank'>34385295<\/a><\/p>\n<p>Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer. Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, Cristobal I, de la Fuente L, Minguez P, Eroles P, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F. International Journal of Molecular Sciences. 2021 Dec 10;22(24):13297. doi: <a href='https:\/\/doi.org\/10.3390\/ijms222413297' target='_blank'>10.3390\/ijms222413297<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34948097' target='_blank'>34948097<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #9da0d2;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-6\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: left;\">Projects<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-2 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-2 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-2 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav,.fusion-tabs.fusion-tabs-2 .nav-tabs,.fusion-tabs.fusion-tabs-2 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-c04291d740fe5a52728\" aria-selected=\"true\" id=\"fusion-tab-projects\" href=\"#tab-c04291d740fe5a52728\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-c04291d740fe5a52728\" aria-selected=\"true\" id=\"mobile-fusion-tab-projects\" href=\"#tab-c04291d740fe5a52728\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-projects\" id=\"tab-c04291d740fe5a52728\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:left;\">\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI21\/01351<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Predicci\u00f3n de enfermedad residual despu\u00e9s de la terapia neoadyuvante en c\u00e1ncer de mama HER2 positivo e identificaci\u00f3n de estrategias para superar la resistencia<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Pilar Eroles Asensio<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>123.420 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI18\/01219<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Caracterizaci\u00f3n y repercusi\u00f3n terap\u00e9utica de la ecolog\u00eda de c\u00e1ncer de mama HER2 positivo<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Pilar Eroles Asensio<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>112.530 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>COST Action CA15204<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>European Platform for Outcomes Research into Perioperative Interventions during Surgery for Cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Pilar Eroles Asensio<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2016 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-7\" style=\"transform:translate3d(0,0,0);\"><h5>+ Info<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-3 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-3 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-3 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav,.fusion-tabs.fusion-tabs-3 .nav-tabs,.fusion-tabs.fusion-tabs-3 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-00436b4af0f0785c427\" aria-selected=\"true\" id=\"fusion-tab-thesis\" href=\"#tab-00436b4af0f0785c427\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-00436b4af0f0785c427\" aria-selected=\"true\" id=\"mobile-fusion-tab-thesis\" href=\"#tab-00436b4af0f0785c427\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-thesis\" id=\"tab-00436b4af0f0785c427\"><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Overcoming resistance to HER2 blockade in breast cancer: AXL as a promising druggable target and prognostic biomarker<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Adam Artigues, Anna<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Lluch Hern\u00e1ndez, Ana; Eroles Asensio, Pilar<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>12\/04\/2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Role of miR-99a-5p in breast cancer: translating molecular findings into clinical tool<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Garrido Cano, Iris<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Eroles Asensio, Pilar; Mart\u00ednez M\u00e1\u00f1ez, Ram\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>17\/12\/2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat Polit\u00e8cnica de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Involvement of EZH2-MYC loop and SALL4 in epithelial-mesenchymal transition (EMT) and trastuzumab resistance process in HER2+ breast cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Pattanayak Pattanayak, Chaudhuri Birlipta<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Eroles Asensio, Pilar; Cejalvo And\u00fajar, Juan Miguel<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>26\/02\/2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Epigenetic regulation of resistance to treatments in triple negative and HER2+ breast cancer: mirnas involved<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Cabello Navarro, Paula<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Erol\u00e9s Asensio, Pilar; Lluch Hern\u00e1ndez, Ana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>28\/09\/2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat Polit\u00e8cnica de Val\u00e8ncia<\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-4{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-4 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-4{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7530"}],"collection":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=7530"}],"version-history":[{"count":0,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7530\/revisions"}],"wp:attachment":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=7530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}